Skip to main content

Advertisement

SpringerLink
Log in

Structural damage in diabetic nephropathy is associated with TNF-α system activity

  • Original Article
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

Abstract

In experimental animal studies, tumour necrosis factor-α (TNF-α) contributed to renal hypertrophy during diabetes, and antibodies against TNF-α have led to improved histological lesions in animals with nephrotoxicity and diabetic nephropathy. We aimed to evaluate TNF-α system activity in association with renal histology in patients with type 2 diabetes. This is a prospective, cross-sectional study of 22 patients with type 2 diabetes (16 men), 13 with microalbuminuria and 9 with normoalbuminuria. Plasma-soluble TNF-α receptor 1 and 2 (sTNFR1 and sTNFR2) concentrations were used as surrogates of TNF-α system activity. Glomerular filtration rate (GFR) was analysed using I125-Iodothalamine. Albumin excretion rate (AER) and a renal biopsy were performed in all subjects. AER did not associate significantly with mesangial expansion or interstitial fraction in these subjects (r < 0.12, P > 0.5). AER was also not associated with either sTNFR1 or sTNFR2 levels. However, after controlling for GFR, the correlation between AER and sTNFR1 became significant (r = 0.47, P = 0.03). sTNFR1 correlated with age (r = 0.65, P < 0.001), mesangial expansion (r = 0.59, P = 0.004) and interstitial fraction (r = 0.58, P = 0.005). After controlling for age, body mass index and blood pressure, the association of TNFR1 with mesangial expansion persisted significant. Circulating sTNFR2 concentrations were not significantly associated with histological changes. In summary, structural kidney damage in patients with type 2 diabetes is associated with TNF-α system activity and specifically with plasma sTNFR1 concentrations.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Parving HH, Osterby R, Anderson PW, Hsuch WA (1996) Diabetic nephropathy. In: Brenner BM (ed) The kidney. Saunders, Philadelphia, pp 1864–1922

    Google Scholar 

  2. Hasegawa G, Nakano K, Sawada M et al (1991) Possible tole of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int 40:1007–1012

    Article  PubMed  CAS  Google Scholar 

  3. Vlassara H, Brownlee M, Manogue KR, Dinarello CA, Pasagian A (1988) Cachectin/TNF and IL-1 induced by glucose modified proteins: role in normal tissue remodelling. Science 240:1546–1548

    Article  PubMed  CAS  Google Scholar 

  4. Baund L, Oudinet JP, Marcelle B et al (1989) Production of tumor necrosis factor by rat mesangial cells in response to bacterial lipopolysaccharide. Kidney Int 35:1111–1118

    Article  Google Scholar 

  5. Navarro JF, Mora C, Rivero A et al (1999) Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis 33:458–463

    Article  PubMed  CAS  Google Scholar 

  6. Ortiz A, González-Cuadrado S, Bustos C et al (1995) Tumor necrosis factor as a mediator of glomerular damage. J Nephrol 8:27–34

    Google Scholar 

  7. Ng DP, Fukushima M, Tai BC et al (2008) Reduced GFR and albuminuria in Chinese type 2 diabetes mellitus patients are both independently associated with activation of the TNF-alpha system. Diabetologia 51:2318–2324

    Article  PubMed  CAS  Google Scholar 

  8. Fernández-Real JM, Broch M, Ricart W et al (1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor-2 and insulin resistance. Diabetes 47:1757–1762

    Article  PubMed  Google Scholar 

  9. Adamska A, Nikolajuk A, Karczewska-Kupczewska M et al (2011) Relationships between serum adiponectin and soluble TNF-α receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol (Epub ahead of print)

  10. Wu W, Wang M, Sun Z, Wang X, Miao J, Zheng Z (2011) The predictive value of TNF-alpha and IL-6 and the incidence of macrovascular complications in patients with type 2 diabetes. Acta Diabetol (Epub ahead of print)

  11. Blank SE, Johnson EC, Weeks DK, Wysham CH (2010) Circulating dendritic cell number and intracellular TNF-alpha production in women with type 2 diabetes. Acta Diabetol (Epub ahead of print)

  12. Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O (2011) Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol 48:135–142

    Article  PubMed  CAS  Google Scholar 

  13. Pfeilschifter J, Pignat W, Vosbeck K, Märki F (1989) Interleukin 1 and tumor necrosis factor synergistically stimulate prostaglandin synthesis and phospholipase A2 release from rat mesangial cells. Biochem Biophys Res Commun 159:385–394

    Article  PubMed  CAS  Google Scholar 

  14. Royall JA, Berkow RL, Beckman JS et al (1989) Tumor necrosis factor and interleukin 1 increase vascular endothelial permeability. Am J Physiol 257:L399–L410

    PubMed  CAS  Google Scholar 

  15. Aderka D, Engelmann H, Maor Y, Brakebusch C, Wallach D (1992) Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 175:323–329

    Article  PubMed  CAS  Google Scholar 

  16. Nelson RG, Bennett PH, Beck GJ et al (1996) Development and progression of renal disease in Pima Indians with non insulin dependent diabetes mellitus. N Engl J Med 335:1636–1642

    Article  PubMed  CAS  Google Scholar 

  17. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691–697

    Article  PubMed  CAS  Google Scholar 

  18. DiPetrillo K, Coutermarsh B, Gesek FA (2003) Urinary tumor necrosis factor contributes to sodium retention and renal hypertrophy during diabetes. Am J Physiol Renal Physiol 284:F113–F121

    PubMed  CAS  Google Scholar 

  19. Smith CA, Farrah T, Goodwin RG (1994) The TNF receptor superfamily of cellular and viral proteins: activation, costimulation and death. Cell 76:959–962

    Article  PubMed  CAS  Google Scholar 

  20. Sheikh MS, Huang Y (2003) Death receptor activation complexes: it takes two to activate TNF receptor 1. Cell Cycle 2:550–552

    PubMed  CAS  Google Scholar 

  21. Hofmann MA, Schiekofer S, Isermann B et al (1999) Peripheral blood mononuclear cells isolated from patients with diabetic nephropathy show increased activation of the oxidative-stress sensitive transcription factor NF-κB. Diabetologia 42:222–232

    Article  PubMed  CAS  Google Scholar 

  22. Satriano J, Schlöndorff D (1994) Activation and attenuation of transcription factor NF-κB in mouse glomerular mesangial cells in response to tumor necrosis factor-α, immunoglobulin G and adenosine 3′ 5′-cyclic monophosphate. J Clin Invest 94:1629–1636

    Article  PubMed  CAS  Google Scholar 

  23. Hruby AW, Shirota K, Jothy S, Lowry RP (1991) Antiserum against tumor necrosis factor-alpha and a protease inhibitor reduce glomerular injury. Kidney Int 40:43–51

    Article  PubMed  CAS  Google Scholar 

  24. Moriwaki Y, Inokuchi T, Yamamoto A et al (2007) Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 44:215–218

    Article  PubMed  CAS  Google Scholar 

  25. Menghini R, Menini S, Amoruso R et al (2009) Tissue inhibitor of metalloproteinase 3 deficiency causes hepatic steatosis and adipose tissue inflammation in mice. Gastroenterology 136:663–672

    Article  PubMed  CAS  Google Scholar 

  26. Serino M, Menghini R, Fiorentino L et al (2007) Mice heterozygous for tumor necrosis factor-alpha converting enzyme are protected from obesity-induced insulin resistance and diabetes. Diabetes 56:2541–2546

    Article  PubMed  CAS  Google Scholar 

  27. Guerrero-Romero F, Rodriguez-Moran M, Paniagua-Sierra JR et al (1995) Pentoxifylline reduces proteinuria in insulin-dependent and non insulin-dependent diabetic patients. Clin Nephrol 43:116–121

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Diabetes, Endocrinology and Nutrition, and CIBEROBN Fisiopatología de la Obesidad y Nutrición, University Hospital of Girona “Dr. Josep Trueta”, Carretera de França s/n, 17007, Girona, Spain

    José Manuel Fernández-Real & Wifredo Ricart

  2. Unitat de Endocrinologia i Nutrició, University Hospital of Tarragona “Joan XXIII”, and CIBERDEM, Tarragona, Spain

    Joan Vendrell

  3. Servei de Nefrologia, University Hospital of Girona “Dr. Josep Trueta”, Girona, Spain

    Isabel García & Martí Vallès

Authors
  1. José Manuel Fernández-Real
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Vendrell
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Isabel García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wifredo Ricart
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martí Vallès
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to José Manuel Fernández-Real.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fernández-Real, J.M., Vendrell, J., García, I. et al. Structural damage in diabetic nephropathy is associated with TNF-α system activity. Acta Diabetol 49, 301–305 (2012). https://doi.org/10.1007/s00592-011-0349-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-011-0349-y

Keywords

Search

Navigation